Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population
There is little information about weight gain induced by antipsychotics at long-term. To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment. This is a prospective, rand...
Saved in:
| Published in | Schizophrenia research Vol. 99; no. 1; pp. 13 - 22 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Amsterdam
Elsevier B.V
01.02.2008
Elsevier Science |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | There is little information about weight gain induced by antipsychotics at long-term.
To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment.
This is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted.
A total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (±
4.1) for haloperidol, 5.9 kg (±
5.1) for risperidone and 8.4 kg (±
5.0) for olanzapine (
F
=
7.045;
p
=
0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (±
5.7) for haloperidol, 8.9 kg (±
8.8) for risperidone and 10.9 kg (±
7.2) for olanzapine (
F
=
0.817;
p
=
0.445).
Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain. |
|---|---|
| AbstractList | AbstractBackgroundThere is little information about weight gain induced by antipsychotics at long-term. ObjectiveTo quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment. MethodsThis is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted. ResultsA total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (± 4.1) for haloperidol, 5.9 kg (± 5.1) for risperidone and 8.4 kg (± 5.0) for olanzapine ( F= 7.045; p= 0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (± 5.7) for haloperidol, 8.9 kg (± 8.8) for risperidone and 10.9 kg (± 7.2) for olanzapine ( F= 0.817; p= 0.445). ConclusionsDrug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain. There is little information about weight gain induced by antipsychotics at long-term.BACKGROUNDThere is little information about weight gain induced by antipsychotics at long-term.To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment.OBJECTIVETo quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment.This is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted.METHODSThis is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted.A total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (+/-4.1) for haloperidol, 5.9 kg (+/-5.1) for risperidone and 8.4 kg (+/-5.0) for olanzapine (F=7.045; p=0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (+/-5.7) for haloperidol, 8.9 kg (+/-8.8) for risperidone and 10.9 kg (+/-7.2) for olanzapine (F=0.817; p=0.445).RESULTSA total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (+/-4.1) for haloperidol, 5.9 kg (+/-5.1) for risperidone and 8.4 kg (+/-5.0) for olanzapine (F=7.045; p=0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (+/-5.7) for haloperidol, 8.9 kg (+/-8.8) for risperidone and 10.9 kg (+/-7.2) for olanzapine (F=0.817; p=0.445).Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain.CONCLUSIONSDrug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain. There is little information about weight gain induced by antipsychotics at long-term. To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment. This is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted. A total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (± 4.1) for haloperidol, 5.9 kg (± 5.1) for risperidone and 8.4 kg (± 5.0) for olanzapine ( F = 7.045; p = 0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (± 5.7) for haloperidol, 8.9 kg (± 8.8) for risperidone and 10.9 kg (± 7.2) for olanzapine ( F = 0.817; p = 0.445). Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain. There is little information about weight gain induced by antipsychotics at long-term. To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment. This is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted. A total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (+/-4.1) for haloperidol, 5.9 kg (+/-5.1) for risperidone and 8.4 kg (+/-5.0) for olanzapine (F=7.045; p=0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (+/-5.7) for haloperidol, 8.9 kg (+/-8.8) for risperidone and 10.9 kg (+/-7.2) for olanzapine (F=0.817; p=0.445). Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain. |
| Author | Pelayo-Teran, Jose M. Garcia-Unzueta, Maria T. Crespo-Facorro, Benedicto Alvarez-Jimenez, Mario Perez-Iglesias, Rocio Ramirez-Bonilla, Maria L. Amado, Jose A. Martinez-Garcia, Obdulia Vazquez-Barquero, Jose L. |
| Author_xml | – sequence: 1 givenname: Rocio surname: Perez-Iglesias fullname: Perez-Iglesias, Rocio organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 2 givenname: Benedicto surname: Crespo-Facorro fullname: Crespo-Facorro, Benedicto email: bcfacorro@humv.es organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 3 givenname: Obdulia surname: Martinez-Garcia fullname: Martinez-Garcia, Obdulia organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 4 givenname: Maria L. surname: Ramirez-Bonilla fullname: Ramirez-Bonilla, Maria L. organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 5 givenname: Mario surname: Alvarez-Jimenez fullname: Alvarez-Jimenez, Mario organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 6 givenname: Jose M. surname: Pelayo-Teran fullname: Pelayo-Teran, Jose M. organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 7 givenname: Maria T. surname: Garcia-Unzueta fullname: Garcia-Unzueta, Maria T. organization: Department of Endocrinology, Marqués de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 8 givenname: Jose A. surname: Amado fullname: Amado, Jose A. organization: Department of Endocrinology, Marqués de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain – sequence: 9 givenname: Jose L. surname: Vazquez-Barquero fullname: Vazquez-Barquero, Jose L. organization: Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20147425$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18053689$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkkuO1DAQhrMYxDzgBgh5Ayu6KTtOnIwQEhoxgDQSC0AsrYpT6XGTtoOdjNRzC27ADbgDXAyH7pkFEiA2fpS--stVv4-zA-cdZdkDDksOvHy6XkZzGSguBYBKoSUIcZAdQS1gUdelPMyOY1wDAC9A3c0OeQVFXlb1UfblI9nV5chWaB2zrp0MtazZskvs_UDBtr5_woKNu7Mjhq5lvkd3jYOdr91IgfHvX7eE4ZSdJwnrVpH5jiELCfYbe50kTW-dNdizMdi0pmLI2jCtFg5_fLsiNvhh6nG03t3L7nTYR7q_30-yD-cv35-9Xly8ffXm7MXFwhSlHBcNp6rBrhMcpeG1KKraVFh0wiAvTKVMK1A1WBneSKiaMjdlrqSqZJNjk4L5SfZ4pzsE_3miOOqNjYb61Bv5KWoFuZACRAIf7sGp2VCrh2A3GLb6ZogJeLQHMKYWu9S2sfGWE8ClkqJI3OmOM8HHGKjTxo6_eh4D2l5z0LObeq13burZzTma3EzJ8rfk23f8Pe35Lo3SKK8shQRZcsllG8iMuvX2fwVurPxEW4prPwWXbNJcR6FBv5v_3PzlQAHIUqkk8OzPAv-u_xOiDOoe |
| CitedBy_id | crossref_primary_10_1016_j_ejps_2017_03_050 crossref_primary_10_1016_j_ajp_2023_103594 crossref_primary_10_1016_j_ajp_2012_05_005 crossref_primary_10_17826_cumj_569373 crossref_primary_10_1177_1039856218810166 crossref_primary_10_1177_2045125313507738 crossref_primary_10_1016_j_schres_2009_03_025 crossref_primary_10_1016_j_schres_2010_12_008 crossref_primary_10_1016_S2173_5050_10_70025_X crossref_primary_10_1016_j_mppsy_2008_08_001 crossref_primary_10_1093_ijnp_pyad029 crossref_primary_10_1111_jhn_12752 crossref_primary_10_1007_s00213_017_4763_x crossref_primary_10_1016_j_rpsmen_2011_07_001 crossref_primary_10_1002_14651858_CD013337_pub2 crossref_primary_10_1186_s12991_023_00472_z crossref_primary_10_1002_j_2051_5545_2008_tb00182_x crossref_primary_10_1177_0269881115602490 crossref_primary_10_2165_11599080_000000000_00000 crossref_primary_10_1176_appi_focus_140308 crossref_primary_10_1192_bjp_bp_109_066217 crossref_primary_10_1192_j_eurpsy_2023_2417 crossref_primary_10_1017_S1092852900004284 crossref_primary_10_1016_j_schres_2011_06_006 crossref_primary_10_3389_fpsyt_2020_00566 crossref_primary_10_3389_fpsyt_2014_00137 crossref_primary_10_1097_MED_0b013e32833de61c crossref_primary_10_1016_j_schres_2008_05_021 crossref_primary_10_3389_fpsyt_2018_00622 crossref_primary_10_1097_JCP_0b013e3181fae248 crossref_primary_10_1159_000480525 crossref_primary_10_1016_j_euroneuro_2011_06_005 crossref_primary_10_1177_070674371005500305 crossref_primary_10_3310_pgfar08010 crossref_primary_10_1016_j_schres_2010_06_002 crossref_primary_10_1002_14651858_CD013338 crossref_primary_10_1016_j_jacl_2015_08_002 crossref_primary_10_1002_14651858_CD013337 crossref_primary_10_1080_14999013_2023_2218287 crossref_primary_10_1089_cap_2010_0020 crossref_primary_10_1097_YCO_0b013e3283130fb7 crossref_primary_10_1097_YCO_0b013e32833f46c9 crossref_primary_10_1007_s00213_016_4324_8 crossref_primary_10_1016_j_psychres_2022_114680 crossref_primary_10_1016_j_rpsm_2012_03_006 crossref_primary_10_1186_1744_859X_10_22 crossref_primary_10_1097_YIC_0b013e3283377850 crossref_primary_10_1097_YIC_0b013e32832b6bf6 crossref_primary_10_1002_14651858_CD006629_pub2 crossref_primary_10_1016_j_psychres_2019_01_068 crossref_primary_10_1111_j_1751_7893_2011_00262_x crossref_primary_10_1016_j_rpsm_2011_07_003 crossref_primary_10_1002_14651858_CD013425_pub2 crossref_primary_10_2165_00023210_200822070_00002 crossref_primary_10_1016_j_euroneuro_2015_03_002 crossref_primary_10_1016_j_obpill_2022_100017 crossref_primary_10_1016_j_rpsmen_2011_12_003 crossref_primary_10_1017_S1461145713001053 crossref_primary_10_1111_j_1467_789X_2009_00589_x crossref_primary_10_1111_j_1742_1241_2009_02224_x crossref_primary_10_1002_14651858_CD011127 crossref_primary_10_1089_cap_2010_0011 crossref_primary_10_1177_0269881110388332 crossref_primary_10_1097_YCO_0b013e328314b74b crossref_primary_10_1177_0269881112473789 crossref_primary_10_1080_17430437_2016_1173910 crossref_primary_10_2165_11530020_000000000_00000 crossref_primary_10_2147_NDT_S358392 crossref_primary_10_1016_j_jacl_2014_10_002 crossref_primary_10_1016_j_neubiorev_2017_01_029 crossref_primary_10_1038_s41598_021_94700_9 crossref_primary_10_1111_eip_12251 crossref_primary_10_1097_JCP_0b013e318172b8d5 crossref_primary_10_3109_08039488_2010_500397 crossref_primary_10_1016_j_psychres_2012_07_005 crossref_primary_10_3389_fpsyt_2024_1491417 crossref_primary_10_1016_j_schres_2008_01_028 crossref_primary_10_1016_j_schres_2009_10_012 crossref_primary_10_1007_s11920_008_0034_1 crossref_primary_10_1111_j_1600_0447_2008_01334_x crossref_primary_10_1016_j_euroneuro_2010_07_002 crossref_primary_10_1002_pds_1490 crossref_primary_10_1016_j_rpsm_2010_08_001 crossref_primary_10_1016_j_psyneuen_2013_09_023 crossref_primary_10_1016_j_schres_2008_09_028 crossref_primary_10_1017_S0033291709990407 crossref_primary_10_1002_npr2_12193 crossref_primary_10_52667_2712_9179_2025_5_1_16_26 crossref_primary_10_1097_JCP_0b013e318172b8e6 |
| Cites_doi | 10.1056/NEJMoa051688 10.1016/j.schres.2007.02.024 10.1192/bjp.187.6.537 10.1038/sj.npp.1300157 10.1097/01.jcp.0000222513.63767.de 10.4088/JCP.v68n1113 10.1136/bmj.321.7273.1371 10.1016/j.euroneuro.2006.06.003 10.1176/appi.ajp.162.5.947 10.1001/jama.290.20.2693 10.1176/appi.ajp.162.8.1535 10.1111/j.1600-0447.1987.tb10566.x 10.2165/00002018-200629040-00002 10.1176/ajp.154.4.457 10.1176/appi.ajp.161.3.414 10.1176/appi.ajp.158.5.765 10.4088/JCP.v67n1004 10.1176/ajp.156.11.1686 |
| ContentType | Journal Article |
| Copyright | 2007 Elsevier B.V. Elsevier B.V. 2008 INIST-CNRS |
| Copyright_xml | – notice: 2007 Elsevier B.V. – notice: Elsevier B.V. – notice: 2008 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.schres.2007.10.022 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EndPage | 22 |
| ExternalDocumentID | 18053689 20147425 10_1016_j_schres_2007_10_022 S0920996407004677 1_s2_0_S0920996407004677 |
| Genre | Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c564t-b1e8baff21a4c192589c8a5f2ca15c87cd2a7ba8c1b408b63c6374784b3abc1b3 |
| IEDL.DBID | .~1 |
| ISSN | 0920-9964 |
| IngestDate | Wed Jul 30 10:52:23 EDT 2025 Mon Jul 21 05:53:08 EDT 2025 Wed Apr 23 03:05:26 EDT 2025 Tue Jul 01 04:00:06 EDT 2025 Thu Apr 24 22:59:38 EDT 2025 Sun Apr 06 06:53:02 EDT 2025 Sun Feb 23 10:19:43 EST 2025 Tue Aug 26 16:31:20 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | First episode psychosis Antipsychotics Olanzapine Long-term Haloperidol Risperidone Weight gain Human Atypical antipsychotic Psychotropic Neuroleptic Dopamine antagonist Serotonin antagonist Pharmacotherapy Controlled therapeutic trial Butyrophenone derivatives Serotonine receptor Long term Thienobenzodiazepine derivatives Psychosis D2 Dopamine receptor Treatment First episode Benzisoxazole derivatives |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c564t-b1e8baff21a4c192589c8a5f2ca15c87cd2a7ba8c1b408b63c6374784b3abc1b3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 18053689 |
| PQID | 70324202 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_70324202 pubmed_primary_18053689 pascalfrancis_primary_20147425 crossref_citationtrail_10_1016_j_schres_2007_10_022 crossref_primary_10_1016_j_schres_2007_10_022 elsevier_sciencedirect_doi_10_1016_j_schres_2007_10_022 elsevier_clinicalkeyesjournals_1_s2_0_S0920996407004677 elsevier_clinicalkey_doi_10_1016_j_schres_2007_10_022 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-02-01 |
| PublicationDateYYYYMMDD | 2008-02-01 |
| PublicationDate_xml | – month: 02 year: 2008 text: 2008-02-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Amsterdam |
| PublicationPlace_xml | – name: Amsterdam – name: Netherlands |
| PublicationTitle | Schizophrenia research |
| PublicationTitleAlternate | Schizophr Res |
| PublicationYear | 2008 |
| Publisher | Elsevier B.V Elsevier Science |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Science |
| References | Schooler, Rabinowitz, Davidson, Emsley, Harvey, Kopala, McGorry, Van Hove, Eerdekens, Swyzen, De Smedt (bib17) 2005; 162 Gentile (bib9) 2006; 29 Geddes, Freemantle, Harrison, Bebbington (bib8) 2000; 321 Crespo-Facorro, Perez-Iglesias, Ramirez-Bonilla, Martinez-Garcia, Llorca, Luis Vazquez-Barquero (bib7) 2006; 67 Strassnig, Miewald, Keshavan, Ganguli (bib19) 2007; 93 Newcomer (bib14) 2005; 19 Conley, Mahmoud (bib5) 2001; 158 Correll, Leucht, Kane (bib6) 2004; 161 Lieberman, Stroup, McEvoy, Swartz, Rosenheck, Perkins, Keefe, Davis, Davis, Lebowitz, Severe, Hsiao (bib12) 2005; 353 Rosenheck, Perlick, Bingham, Liu-Mares, Collins, Warren, Leslie, Allan, Campbell, Caroff, Corwin, Davis, Douyon, Dunn, Evans, Frecska, Grabowski, Graeber, Herz, Kwon, Lawson, Mena, Sheikh, Smelson, Smith-Gamble (bib16) 2003; 290 Andreasen (bib3) 1983 Andreasen (bib4) 1984 Zipursky, Gu, Green, Perkins, Tohen, McEvoy, Strakowski, Sharma, Kahn, Gur, Tollefson, Lieberman (bib21) 2005; 187 Allison, Mentore, Heo, Chandler, Cappelleri, Infante, Weiden (bib1) 1999; 156 Simpson, Weiden, Pigott, Murray, Siu, Romano (bib18) 2005; 162 Lieberman, Phillips, Gu, Stroup, Zhang, Kong, Ji, Koch, Hamer (bib11) 2003; 28 Lingjaerde, Ahlfors, Bech, Dencker, Elgen (bib13) 1987; 334 Alvarez, Ciudad, Olivares, Bousono, Gomez (bib2) 2006; 26 Perez-Iglesias, Crespo-Facorro, Amado, Garcia-Unzueta, Ramirez-Bonilla, Gonzalez-Blanch, Martinez-Garcia, Ramirez-Bonilla (bib15) 2007; 68 Haupt (bib10) 2006; 16 Tollefson, Beasley, Tran, Street, Krueger, Tamura, Graffeo, Thieme (bib20) 1997; 154 Zipursky (10.1016/j.schres.2007.10.022_bib21) 2005; 187 Alvarez (10.1016/j.schres.2007.10.022_bib2) 2006; 26 Gentile (10.1016/j.schres.2007.10.022_bib9) 2006; 29 Strassnig (10.1016/j.schres.2007.10.022_bib19) 2007; 93 Andreasen (10.1016/j.schres.2007.10.022_bib4) 1984 Crespo-Facorro (10.1016/j.schres.2007.10.022_bib7) 2006; 67 Lingjaerde (10.1016/j.schres.2007.10.022_bib13) 1987; 334 Lieberman (10.1016/j.schres.2007.10.022_bib11) 2003; 28 Conley (10.1016/j.schres.2007.10.022_bib5) 2001; 158 Haupt (10.1016/j.schres.2007.10.022_bib10) 2006; 16 Simpson (10.1016/j.schres.2007.10.022_bib18) 2005; 162 Newcomer (10.1016/j.schres.2007.10.022_bib14) 2005; 19 Tollefson (10.1016/j.schres.2007.10.022_bib20) 1997; 154 Rosenheck (10.1016/j.schres.2007.10.022_bib16) 2003; 290 Schooler (10.1016/j.schres.2007.10.022_bib17) 2005; 162 Correll (10.1016/j.schres.2007.10.022_bib6) 2004; 161 Lieberman (10.1016/j.schres.2007.10.022_bib12) 2005; 353 Allison (10.1016/j.schres.2007.10.022_bib1) 1999; 156 Geddes (10.1016/j.schres.2007.10.022_bib8) 2000; 321 Andreasen (10.1016/j.schres.2007.10.022_bib3) 1983 Perez-Iglesias (10.1016/j.schres.2007.10.022_bib15) 2007; 68 18952965 - Evid Based Ment Health. 2008 Nov;11(4):116 |
| References_xml | – volume: 161 start-page: 414 year: 2004 end-page: 425 ident: bib6 article-title: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies publication-title: Am. J. Psychiatry – volume: 19 start-page: 1 year: 2005 end-page: 93 ident: bib14 article-title: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review publication-title: CNS Drugs – volume: 156 start-page: 1686 year: 1999 end-page: 1696 ident: bib1 article-title: Antipsychotic-induced weight gain: a comprehensive research synthesis publication-title: Am. J. Psychiatry – year: 1984 ident: bib4 article-title: Scale for the Assessment of Positive Symptoms (SAPS) – volume: 321 start-page: 1371 year: 2000 end-page: 1376 ident: bib8 article-title: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis publication-title: BMJ – volume: 67 start-page: 1511 year: 2006 end-page: 1521 ident: bib7 article-title: A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis publication-title: J. Clin. Psychiatry – volume: 353 start-page: 1209 year: 2005 end-page: 1223 ident: bib12 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: N. Engl. J. Med. – year: 1983 ident: bib3 article-title: Scale for the Assessment of Negative symptoms (SANS) – volume: 16 start-page: S149 year: 2006 end-page: S155 ident: bib10 article-title: Differential metabolic effects of antipsychotic treatments publication-title: Eur. Neuropsychopharmacol. – volume: 334 start-page: 1 year: 1987 end-page: 100 ident: bib13 article-title: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients publication-title: Acta Psychiatr. Scand. Suppl. – volume: 158 start-page: 765 year: 2001 end-page: 774 ident: bib5 article-title: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder publication-title: Am. J. Psychiatry – volume: 290 start-page: 2693 year: 2003 end-page: 2702 ident: bib16 article-title: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial publication-title: JAMA – volume: 26 start-page: 238 year: 2006 end-page: 249 ident: bib2 article-title: A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia publication-title: J. Clin. Psychopharmacol. – volume: 29 start-page: 303 year: 2006 end-page: 319 ident: bib9 article-title: Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis publication-title: Drug Saf. – volume: 162 start-page: 1535 year: 2005 end-page: 1538 ident: bib18 article-title: Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia publication-title: Am. J. Psychiatry – volume: 154 start-page: 457 year: 1997 end-page: 465 ident: bib20 article-title: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial publication-title: Am. J. Psychiatry – volume: 68 start-page: 1733 year: 2007 end-page: 1740 ident: bib15 article-title: A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug Naïve First-Episode Psychosis Patients Treated with Haloperidol, Olanzapine or Risperidone publication-title: J. Clin. Psychiatry – volume: 28 start-page: 995 year: 2003 end-page: 1003 ident: bib11 article-title: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine publication-title: Neuropsychopharmacology – volume: 187 start-page: 537 year: 2005 end-page: 543 ident: bib21 article-title: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol publication-title: Br. J. Psychiatry – volume: 162 start-page: 947 year: 2005 end-page: 953 ident: bib17 article-title: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial publication-title: Am. J. Psychiatry – volume: 93 start-page: 90 year: 2007 end-page: 98 ident: bib19 article-title: Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis publication-title: Schizophr. Res. – volume: 353 start-page: 1209 year: 2005 ident: 10.1016/j.schres.2007.10.022_bib12 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa051688 – volume: 93 start-page: 90 year: 2007 ident: 10.1016/j.schres.2007.10.022_bib19 article-title: Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis publication-title: Schizophr. Res. doi: 10.1016/j.schres.2007.02.024 – volume: 187 start-page: 537 year: 2005 ident: 10.1016/j.schres.2007.10.022_bib21 article-title: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol publication-title: Br. J. Psychiatry doi: 10.1192/bjp.187.6.537 – volume: 28 start-page: 995 year: 2003 ident: 10.1016/j.schres.2007.10.022_bib11 article-title: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300157 – volume: 26 start-page: 238 year: 2006 ident: 10.1016/j.schres.2007.10.022_bib2 article-title: A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia publication-title: J. Clin. Psychopharmacol. doi: 10.1097/01.jcp.0000222513.63767.de – volume: 68 start-page: 1733 year: 2007 ident: 10.1016/j.schres.2007.10.022_bib15 article-title: A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug Naïve First-Episode Psychosis Patients Treated with Haloperidol, Olanzapine or Risperidone publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.v68n1113 – volume: 321 start-page: 1371 year: 2000 ident: 10.1016/j.schres.2007.10.022_bib8 article-title: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis publication-title: BMJ doi: 10.1136/bmj.321.7273.1371 – volume: 16 start-page: S149 issue: Suppl 3 year: 2006 ident: 10.1016/j.schres.2007.10.022_bib10 article-title: Differential metabolic effects of antipsychotic treatments publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2006.06.003 – volume: 162 start-page: 947 year: 2005 ident: 10.1016/j.schres.2007.10.022_bib17 article-title: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.162.5.947 – year: 1983 ident: 10.1016/j.schres.2007.10.022_bib3 – volume: 290 start-page: 2693 year: 2003 ident: 10.1016/j.schres.2007.10.022_bib16 article-title: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.290.20.2693 – volume: 162 start-page: 1535 year: 2005 ident: 10.1016/j.schres.2007.10.022_bib18 article-title: Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.162.8.1535 – volume: 334 start-page: 1 year: 1987 ident: 10.1016/j.schres.2007.10.022_bib13 article-title: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients publication-title: Acta Psychiatr. Scand. Suppl. doi: 10.1111/j.1600-0447.1987.tb10566.x – volume: 29 start-page: 303 year: 2006 ident: 10.1016/j.schres.2007.10.022_bib9 article-title: Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis publication-title: Drug Saf. doi: 10.2165/00002018-200629040-00002 – year: 1984 ident: 10.1016/j.schres.2007.10.022_bib4 – volume: 154 start-page: 457 year: 1997 ident: 10.1016/j.schres.2007.10.022_bib20 article-title: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial publication-title: Am. J. Psychiatry doi: 10.1176/ajp.154.4.457 – volume: 161 start-page: 414 year: 2004 ident: 10.1016/j.schres.2007.10.022_bib6 article-title: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.161.3.414 – volume: 19 start-page: 1 issue: Suppl. 1 year: 2005 ident: 10.1016/j.schres.2007.10.022_bib14 article-title: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review publication-title: CNS Drugs – volume: 158 start-page: 765 year: 2001 ident: 10.1016/j.schres.2007.10.022_bib5 article-title: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.158.5.765 – volume: 67 start-page: 1511 year: 2006 ident: 10.1016/j.schres.2007.10.022_bib7 article-title: A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.v67n1004 – volume: 156 start-page: 1686 year: 1999 ident: 10.1016/j.schres.2007.10.022_bib1 article-title: Antipsychotic-induced weight gain: a comprehensive research synthesis publication-title: Am. J. Psychiatry doi: 10.1176/ajp.156.11.1686 – reference: 18952965 - Evid Based Ment Health. 2008 Nov;11(4):116 |
| SSID | ssj0001507 |
| Score | 2.230275 |
| Snippet | There is little information about weight gain induced by antipsychotics at long-term.
To quantify the weight gain induced by first (haloperidol) and second... AbstractBackgroundThere is little information about weight gain induced by antipsychotics at long-term. ObjectiveTo quantify the weight gain induced by first... There is little information about weight gain induced by antipsychotics at long-term.BACKGROUNDThere is little information about weight gain induced by... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 13 |
| SubjectTerms | Adolescent Adult Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Antipsychotics Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Biological and medical sciences Body Mass Index Chronic Disease Cohort Studies Dose-Response Relationship, Drug Female First episode psychosis Follow-Up Studies Haloperidol Haloperidol - adverse effects Haloperidol - therapeutic use Humans Long-term Long-Term Care Male Medical sciences Middle Aged Neuropharmacology Olanzapine Pharmacology. Drug treatments Psychiatric/Mental Health Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Risperidone Risperidone - adverse effects Risperidone - therapeutic use Spain Treatment Outcome Weight gain Weight Gain - drug effects |
| Title | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920996407004677 https://www.clinicalkey.es/playcontent/1-s2.0-S0920996407004677 https://dx.doi.org/10.1016/j.schres.2007.10.022 https://www.ncbi.nlm.nih.gov/pubmed/18053689 https://www.proquest.com/docview/70324202 |
| Volume | 99 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqckFCCFQey2PxgSNm83ASh1tVsdqC6AUqerP8LEFLEjW7SO2B_8A_4B_wH-CPMRMnWyqoirglThw74_E3M8k8CHnqQAaBFNCsNKVmPPOcaV5aJrg1OvIAy30S1zcH-eKQvzrKjrbI3hgLg26VA_YHTO_RemiZDdSctVU1exuVGPaJP6LQyCswopzzArn8-ZdzNw9UePp8e2Am4d1j-Fzv4wUGJBi1IZEh-nglyWXi6UarOiCaD9UuLldHe7E0v0VuDvok3Q1Tvk22XL1Dvr7vP3jSYzD7KRjdsHyW6lP6QS0bzGxsm-UzCrs7HNeOqtpSsHHrM9VWeIqFw2n849sp7IMXdF71oS8dbTxVFOZmm0_VGTxyDKukfe0PGAku25P1MavVz--fHW031cHukMP5y3d7CzbUXmAmy_mK6dgJrbxPYsUNaIGZKI1QmU-MijMjCmMTVWglTKx5JHSemjzFVPxcp0pDY3qXbNfwAvcJ1RaMzNR4sEUz7k2hIsW1404Yl3ir_ISkI8mlGRKTY32MpRw90D7KsFBYM7PAVlioCWGbXm1IzHHF_dm4mnKkDsCkBMlxRb_ib_1cN-z1TsayS2Qk_-DH33teYOl_GHN6gd02LwjaGi8AZSfkych_EuAA__Go2jXrTgKAg9IVwSPuBbY8J44AvM1F-eC_p_WQXA_eMujM84hsr07W7jGoZCs97ffclFzb3X-9OPgFhrA69w |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKWYBUIRCvKaX1giVm8nASh11VdTRA2w2t6M7yswQNSdTMILUL_oE_4A_4B_ixXtvJlAqqInaJJ06c6_s6k_tA6IUBGwRWQJJSlZLQzFIiaakJo1rJyIJa9kVc9w_y6RF9e5wdr6CdIRfGhVX2uj_odK-t-5FxT81xW1Xj91Hp0j7dhygH8oriFrpNQXxdG4NXXy_jPJzH4wvuAU5ylw_5cz7ICxAkoNpQydAFeSXJdfZprRUdUM2GdhfX-6PeLk3uo3u9Q4m3w5ofoBVTP0TfPvh_PPEJ4H4MqBv2T2N5hj-KWeNKG-tm9hKDeIfj2mBRawwgtz4XbeVOXedwHP_8fgaC8BpPKp_70uHGYoFhbbr5XJ3DLYe8Suybf8CT4Gd9ujghtfj144vB7bI92CN0NNk93JmSvvkCUVlO50TGhklhbRILqsANzFipmMhsokScKVYonYhCCqZiSSMm81TlqavFT2UqJAymj9FqDS_wFGGpAWWmygIYzahVhYgElYYapkxitbAjlA4k56qvTO4aZMz4EIL2iYeNck0zCzcKGzVCZDmrDZU5brg-G3aTD9QBPcnBdNwwr_jbPNP1wt7xmHcJj_gfDPn7zCs8_Q_P3LzCbssXBHeNFqBmR2hr4D8O-sB95BG1aRYdBw0OXlcEt3gS2PKSOAwUbs7K9f9e1ha6Mz3c3-N7bw7ePUN3Q-iMi-zZQKvz04V5Dv7ZXG56-bsAXP88hQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Weight+gain+induced+by+haloperidol%2C+risperidone+and+olanzapine+after+1%C2%A0year%3A+Findings+of+a+randomized+clinical+trial+in+a+drug-na%C3%AFve+population&rft.jtitle=Schizophrenia+research&rft.au=Perez-Iglesias%2C+Rocio&rft.au=Crespo-Facorro%2C+Benedicto&rft.au=Martinez-Garcia%2C+Obdulia&rft.au=Ramirez-Bonilla%2C+Maria+L.&rft.date=2008-02-01&rft.issn=0920-9964&rft.volume=99&rft.issue=1-3&rft.spage=13&rft.epage=22&rft_id=info:doi/10.1016%2Fj.schres.2007.10.022&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_schres_2007_10_022 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09209964%2FS0920996408X00039%2Fcov150h.gif |